More than 90% of pulmonary nodules are discovered by accident—or incidentally—and of those, 40% turn out to be cancerous. This is an astounding statistic and the crux of why we do what we do at Eon.
When pulmonary nodules are discovered incidentally, they are most likely spotted in a chest x-ray or CT scan that was performed for a purpose other than suspicion of lung cancer. Usually, early-stage lung cancer is asymptomatic and patients don’t begin to present symptoms until the disease has spread. For critical pulmonary nodule patients, the delay in diagnosing lung cancer can have detrimental effects and may even decrease survivability. This fuels our passion for creating superior solutions that help identify at-risk patients to ensure they have the best chances to fight—and beat—a potential lung cancer diagnosis.
Eon has developed the only actionable findings Eon Patient Management (EPM) platform to positively identify incidental pulmonary nodules with 97% precision. EPM ensures longitudinal care coordination, resulting in earlier cancer diagnoses and giving patients an advantage to fight the disease. Not only does Eon empower clinicians with the identification of these patients, but it automates routine follow-up necessary to save lives.
Saving lives is of utmost importance, but there’s additional value our technology brings. By ensuring patient capture and preventing leakage, Eon boosts hospitals’ bottom line. A retrospective analysis done by our hospital partners found that an identified pulmonary nodule brings on average $3,491 in new downstream revenue to a hospital, and an estimated contribution margin of $1,326.
With this information, Eon has developed a return on investment (ROI) tool that allows facilities to easily project the financial implications of using Eon’s end-to-end patient management platform. The Eon ROI Tool allows for any facility to enter their hospital size and CT volume to pragmatically estimate the return for that hospital.
Identifying, managing, and tracking pulmonary nodule patients is the key to a positive lung cancer stage shift and a prosperous thoracic oncology service line. To do so requires a coordinated balance between technology and human intervention.
To learn more about EPM and how it can help you positively identify incidental pulmonary nodules with 97% precision while boosting hospital revenue streams, contact the Eon Success Team at firstname.lastname@example.org.